EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RAS testing in metastatic colorectal cancer



RAS testing in metastatic colorectal cancer



Zeitschrift für Gastroenterologie 52(9): 1095-1096




(PDF emailed within 0-6 h: $19.90)

Accession: 055333413

Download citation: RISBibTeXText

PMID: 25198090

DOI: 10.1055/s-0034-1384878



Related references

Validation of A Global Economic Model to Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment Using Kras Testing For Cetuximab Therapy In Metastatic Colorectal Cancer. Value in Health 17(7): A559-A559, 2014

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. Journal of Clinical Oncology 12(5): 960-969, 1994

A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. Cancer 119(4): 722-728, 2013

Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clinical Colorectal Cancer 11(4): 247-254, 2013

Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Research 23(2c): 1951-1954, 2003

Testing for RAS mutations in patients with metastatic colorectal cancer. Clinical Advances in Hematology & Oncology 12(1): 48-49, 2015

KRAS mutation testing in metastatic colorectal cancer. World Journal of Gastroenterology 18(37): 5171-5180, 2013

RAS testing in metastatic colorectal cancer: advances in Europe. Virchows Archiv 468(4): 383-396, 2016

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?. Asia-Pacific Journal of Clinical Oncology 10(3): 261-265, 2015

Clinical significance and the handling of KRAS testing on metastatic colorectal cancer. Nihon Rinsho. Japanese Journal of Clinical Medicine 69 Suppl 3: 346-350, 2012

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. Clinical Colorectal Cancer 8(3): 135-140, 2010

HER2 testing in metastatic colorectal cancer: ready for prime time?. Clinical Advances in Hematology & Oncology 14(4): 235-237, 2016

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14(1): 22-28, 2009

Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. Journal of Gastrointestinal Oncology 6(3): 314-321, 2015

Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer. Oncologist 20(1): 14-18, 2015